Caris Life Sciences (CAI) Cash & Equivalents (2024 - 2026)

Caris Life Sciences' Cash & Equivalents history runs 3 years deep, the most recent figure standing at $821.1 million for Q1 2026.

• On a quarterly basis, Cash & Equivalents changed N/A year-over-year to $821.1 million in Q1 2026; TTM through Mar 2026 was $821.1 million, a N/A change from a year earlier, with the FY2025 full-year figure at $797.8 million, up 1119.09% from the prior year.
• Cash & Equivalents improved to $821.1 million in Q1 2026 per CAI's latest filing, from $797.8 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $821.1 million in Q1 2026 and bottomed at $65.4 million in Q4 2024.
• The 3-year median for Cash & Equivalents is $754.7 million (2025), against an average of $631.9 million.
• Biggest YoY gain for Cash & Equivalents was 1119.09% in 2025; the steepest drop was 1119.09% in 2025.
• Year by year, Cash & Equivalents stood at $65.4 million in 2024, then jumped by 1119.09% to $797.8 million in 2025, then increased by 2.93% to $821.1 million in 2026.
• Per Business Quant, the three latest CAI Cash & Equivalents figures stand at $821.1 million (Q1 2026), $797.8 million (Q4 2025), and $754.7 million (Q3 2025).